or Try an Advanced Search...

    Gen Re Stocks List

    Symbol Grade Name % Change
    MBIO F Mustang Bio, Inc. -5.65
    THMO F ThermoGenesis Holdings, Inc. 0.00
    FGF F FG Financial Group, Inc. 0.00
    ACET F Adicet Bio, Inc. 2.37
    ANIX F Anixa Biosciences, Inc. -3.64
    ZNTL F Zentalis Pharmaceuticals, Inc. 5.03
    NTLA F Intellia Therapeutics, Inc. 0.67
    OLMA F Olema Pharmaceuticals, Inc. 3.12
    NKTX D Nkarta, Inc. -4.23
    PSTX D Poseida Therapeutics, Inc. 3.18
    View As Page of Charts
    Related Industries: Biotechnology Coal Diagnostics & Research Food Distribution Insurance - Diversified Insurance - Property & Casualty Insurance - Reinsurance Medical Devices Other
    Related Stock Lists: Chimeric Antigen Receptor Medicine Immune System Biopharmaceutical Cancer Biotechnology Cancer Treatment Chimeric Antigen Receptor T Cell Clinical Medicine Biology Epidermal Growth Factor Receptor Gene Therapy Immunotherapy Antiestrogens Antigen Breast Cancer Cancer Immunotherapy Cellectis Emerging Technologies Estrogen

    Related ETFs - A few ETFs which own one or more of the above listed Gen Re stocks.

    Symbol Grade Name Weight
    ARKG F ARK Genomic Revolution Multi-Sector ETF 3.73
    GNOM D Global X Genomics & Biotechnology ETF 3.68
    ARKK D ARK Innovation ETF 2.43
    SBIO C ALPS Medical Breakthroughs ETF 2.31
    CNCR D Loncar Cancer Immunotherapy ETF 2.02
    View all Gen Re ETFs...
    Compare ETFs
    Compare ARKG to ARKK Compare ARKK to SBIO Compare GNOM to ARKK

        Gen Re Stocks Recent News

        Date Stock Title
        May 7 ANIX Sidoti Events, LLC's Virtual May Micro-Cap Conference
        May 7 ZNTL Zentalis Pharmaceuticals GAAP EPS of $0.14, revenue of $40.56M
        May 7 ACET Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
        May 7 ZNTL Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
        May 6 FGF Fundamental Global Inc. Announces Acquisition of Strong/MDI Screen Systems, Inc. by FG Acquisition Corp. at a $30 Million Valuation
        May 6 ANIX Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja
        May 6 THMO ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
        May 3 NTLA Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
        May 3 NTLA IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
        May 3 PSTX Broker Revenue Forecasts For Poseida Therapeutics, Inc. (NASDAQ:PSTX) Are Surging Higher
        May 2 MBIO Mustang Bio Announces Closing of $4 Million Public Offering
        May 2 NTLA Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
        May 2 PSTX Xyphos and Poseida to develop allogeneic cell therapies for cancer
        May 1 PSTX Poseida gains on cell therapy pact with Astellas
        May 1 PSTX Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
        May 1 OLMA Olema Oncology to Participate in Upcoming Investor Conferences in May
        May 1 PSTX Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
        Related Industries: Biotechnology Coal Diagnostics & Research Food Distribution Insurance - Diversified Insurance - Property & Casualty Insurance - Reinsurance Medical Devices Other
        Related Stock Lists: Chimeric Antigen Receptor Medicine Immune System Biopharmaceutical Cancer Biotechnology Cancer Treatment Chimeric Antigen Receptor T Cell Clinical Medicine Biology Epidermal Growth Factor Receptor Gene Therapy Immunotherapy Antiestrogens Antigen Breast Cancer Cancer Immunotherapy Cellectis Emerging Technologies Estrogen
        Gen Re

        General Reinsurance Corporation is an American multinational property/casualty and life/health reinsurance company offering a range of reinsurance products and services. The company is a direct reinsurer and is represented in all major reinsurance markets worldwide through a network of more than 40 offices and over 3578 employees. Gen Re is a member of the Berkshire Hathaway Inc group of companies.
        Financial strength ratings of Gen Re's reinsurance operations:

        A.M. Best: A++ (Superior)
        Standard & Poor's Claims Paying Ability Rating: AA+General Re Corporation is the holding company for Gen Re's global reinsurance and related operations. It owns General Reinsurance Corporation, General Re Life Corporation and General Reinsurance AG, the direct reinsurers which conduct business as Gen Re. In addition, the insurance, reinsurance and investment management companies in the General Re group include: Gen Re Intermediaries, GR-NEAM, General Star, Genesis, USAU and Faraday.

        More about Gen Re
        Browse All Tags